Market access is one of the most complex and commercially critical challenges facing pharmaceutical companies today. Gaining approval for a new medicine is only the beginning—achieving market access requires demonstrating the product's value to payers, healthcare systems, and regulators in a way that results in reimbursement, formulary listing, and clinical adoption.
Across Europe, market access pathways vary significantly between countries. Health Technology Assessment (HTA) bodies, national formulary committees, and regional payers all apply different criteria when evaluating a medicine's value. Pharmaceutical companies must develop market access strategies that are both robust and flexible enough to succeed across multiple markets.
Effective market access is the bridge between regulatory approval and patient access—it requires evidence, strategy, and deep knowledge of the healthcare ecosystem in every target market.
Price and reimbursement negotiations have become increasingly complex as payers seek to manage healthcare budgets while ensuring access to innovative therapies. Outcomes-based contracts, managed entry agreements, and real-world evidence requirements are becoming standard features of the European market access landscape.
Building a winning market access strategy
A successful market access strategy begins with early planning—ideally integrated into clinical development well before a product reaches the regulatory submission stage. Understanding the evidence requirements of key European HTA bodies, building health economic models, and engaging patient advocacy groups are all critical elements of a comprehensive market access approach.
- Early HTA engagement to align clinical trial design with payer evidence requirements
- Health economic modelling and budget impact analysis for each target market
- Reimbursement dossier preparation and price negotiation strategy
- Real-world evidence generation to support post-launch access and outcomes agreements
- Stakeholder mapping and engagement across payers, HTA bodies, and clinical networks
European Pharma BV supports pharmaceutical manufacturers in navigating European market access pathways, providing distribution, regulatory, and market expertise to help innovative medicines reach the patients who need them.